Piper Jaffray Companies set a $33.00 target price on Phreesia (NYSE:PHR) in a research note released on Tuesday morning, TipRanks reports. The firm currently has a buy rating on the stock.
Other equities research analysts have also recently issued research reports about the stock. William Blair initiated coverage on shares of Phreesia in a report on Monday, August 12th. They issued an outperform rating on the stock. Wells Fargo & Co assumed coverage on shares of Phreesia in a research report on Monday, August 12th. They issued an outperform rating and a $23.00 target price for the company. JPMorgan Chase & Co. assumed coverage on shares of Phreesia in a research note on Tuesday, August 13th. They set an overweight rating and a $33.00 target price for the company. Finally, Chardan Capital initiated coverage on shares of Phreesia in a research note on Tuesday, July 23rd. They set a buy rating and a $33.00 target price for the company. Five analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and an average target price of $30.50.
Shares of PHR traded up $0.29 during mid-day trading on Tuesday, hitting $25.61. 184,581 shares of the company traded hands, compared to its average volume of 279,973. The business has a 50-day moving average price of $26.67. Phreesia has a 1 year low of $22.05 and a 1 year high of $29.38.
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.
Featured Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.